{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oral+dexamethasone&page=20", "query": { "intervention": "oral dexamethasone", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 744, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oral+dexamethasone&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oral+dexamethasone&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T19:17:44.124Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02635984", "title": "Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Complications of Bone Marrow Transplant", "Hematologic Neoplasms" ], "interventions": [ { "name": "Olanzapine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Augusta University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2015-11", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2018-08-20", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635984" }, { "nct_id": "NCT03539744", "title": "A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2018-10-22", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 19, "location_summary": "Tucson, Arizona • Fresno, California • Los Angeles, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03539744" }, { "nct_id": "NCT01188187", "title": "Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Custirsen", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Achieve Life Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1022, "start_date": "2010-11", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2016-10-14", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Marina del Rey, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Marina del Rey", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01188187" }, { "nct_id": "NCT07870447", "title": "Preoperative Celecoxib and Acetaminophen Versus Acetaminophen Alone for Pain Control After Pediatric Adenotonsillectomy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenotonsillectomy", "Postoperative Pain" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 500, "start_date": "2026-11-01", "completion_date": "2029-12-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07870447" }, { "nct_id": "NCT06208150", "title": "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 838, "start_date": "2024-01-22", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 49, "location_summary": "Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06208150" }, { "nct_id": "NCT01615029", "title": "Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Part 1 (Dose Escalation): Daratumumab", "type": "DRUG" }, { "name": "Part 2 (Dose Expansion): Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2012-06-26", "completion_date": "2024-10-23", "has_results": true, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01615029" }, { "nct_id": "NCT01204164", "title": "Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "ALL", "Blast Crisis", "MDS", "Multiple Myeloma" ], "interventions": [ { "name": "TG02 citrate", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tragara Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2010-08", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-05-06", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 9, "location_summary": "Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204164" }, { "nct_id": "NCT03652064", "title": "A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 395, "start_date": "2018-11-06", "completion_date": "2026-04-21", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 19, "location_summary": "Cerritos, California • Jacksonville, Florida • Fort Wayne, Indiana + 15 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03652064" }, { "nct_id": "NCT07479979", "title": "Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapse Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" }, { "name": "Isatuximab SC Wearable Injection System", "type": "DEVICE" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Natalie Callander", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2026-05-21", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07479979" }, { "nct_id": "NCT00179647", "title": "Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1913, "start_date": "2005-09", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2010-03-16", "last_synced_at": "2026-10-24T19:17:44.124Z", "location_count": 63, "location_summary": "Scottsdale, Arizona • Berkeley, California • La Jolla, California + 54 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00179647" } ] }